On the Record · Kamada

Kamada acquisitions, on the record

The businesses Kamada bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
CYTOGAM, HEPGAM B, VARIZIG and WINRHO SDF from Saol Word for word“Following the acquisition of these products in November 2021, we established a U.S. based commercial and sales team which gradually assumed the U.S. commercial responsibility for these products.” 20-F for 2023	acquisition	November 2021	—
plasma collection center and certain related assets from B&PR, Beaumont, Texas Word for word“In March 2021, we completed the acquisition of the FDA licensed plasma collection center and certain related assets from the privately held B&PR based in Beaumont, Texas, which initially specialized in the collection of hyper-immune plasma used in the manufacture KAMRHO (D).” 20-F for 2023	acquisition	March 2021	—
a plasma collection center registered with the FDA and certain related assets from the privately held B&PR based in Beaumont, Texas Word for word“In March 2021, we acquired a plasma collection center registered with the FDA and certain related assets from the privately held B&PR based in Beaumont, Texas, which initially specialized in the collection of hyper-immune plasma used in the manufacture of Rho(D) immunoglobulin, such as KAMRHO (D).” 20-F for 2024	acquisition	In March 2021	—
the portfolio of four FDA-approved products from Saol Word for word“The acquisition of the portfolio of four FDA-approved products in November 2021 resulted in the recognition of significant balances of intangible assets as well as contingent consideration and other long-term liabilities.” 20-F for 2024	acquisition	November 2021	—
CYTOGAM, acquired from Saol Word for word“CYTOGAM, approved by the FDA in 1998, is the sole FDA-approved IgG product for this indication, and was acquired by us from Saol in November 2021.” 20-F for 2024	acquisition	November 2021	—
plasma collection center in Beaumont, Texas Word for word“In March 2021, we acquired our first FDA-licensed plasma collection center in Beaumont, Texas, which specializes in the collection of hyper-immune plasma to be used in the manufacture of WINRHO SDF, KAMRAB and KEDRAB.” 20-F for 2025	acquisition	March 2021	—
WINRHO SDF, from Saol (portfolio of four FDA-approved products) Word for word“WINRHO SDF, approved by the FDA in 1995, which we acquired from Saol in November 2021.” 20-F for 2025	acquisition	November 2021	—

Read from Kamada’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.